Zimmer Biomet increases its share repurchase authorization by $250M, targeting up to $1B in buybacks by year-end 2026.
Zimmer Biomet Holdings raised its share repurchase target to $1B for fiscal year 2026, increasing the prior plan by $250M. The company expects all buybacks to occur under its existing program.
The revised target follows a previously announced repurchase plan, which had not yet reached the $1B threshold. No changes to capital allocation priorities were disclosed alongside the update.
The announcement did not include immediate market reaction details or additional financial guidance.